MDOI Convergence Chronicles 110.0673/CON.2026.00645
110.0673/CON.2026.00645
Article

Patient-Reported Outcomes Now and Into the Future: Multistakeholder Perspectives on Optimizing the Use of Patient-Reported Outcome Evidence in Decision Making Across the US Healthcare Continuum

Sharan Randhawa, MSc, Adam Gater, MSc, Roy Bentley, PhD, JD, MSc, on behalf of the expert stakeholder group 2025 Convergence Chronicles

Abstract

Objectives Patient-reported outcome measures (PROMs) are tools intended to capture directly from patients how they feel and/or function. They can provide important evidence to support regulatory approval, product labeling, payer reimbursement, and clinical care decisions. However, patient-reported outcome (PRO) evidence remains underutilized in regulatory, payer, and overall healthcare decision making. This initiative aimed to understand stakeholder perspectives regarding current use of PRO evidence across the US healthcare continuum and opportunities to further advance its use in healthcare-related decision making. Methods A total of 3 roundtable meetings were convened with an expert panel representing patients/patient advocacy groups, clinicians, PRO experts, payers/purchasers, and policy makers. Meetings were audio recorded, and transcripts were reviewed to identify key discussion points and themes via thematic analysis methods. Group members reviewed, discussed, and commented on findings as they emerged. Results The themes that emerged on maximizing use of PRO evidence were (1) educating stakeholders on its value, (2) ensuring standardization of PROM development methods, including maximizing patient engagement, (3) addressing PROM implementation considerations in clinical trials and practice, (4) effectively communicating PRO evidence to stakeholders, and (5) encouraging PRO evidence integration into policy and shared clinical decision-making. A 5-component framework had resulted. Conclusions PRO evidence is fundamental to patient-focused drug development and clinical care. Collaboration among all stakeholders making decisions related to treatment approval, access, and use is critical to realizing the value of PRO evidence, alongside greater stakeholder transparency on how PRO evidence is used to inform decisions. The 5-component framework, codeveloped by a multistakeholder expert panel, can help to support and enhance these collaborations.

Identifier Metadata

Identifier 110.0673/CON.2026.00645
Canonical mdoi:110.0673/CON.2026.00645
Resolver URL https://mdoi.org/110.0673/CON.2026.00645
Resource URL Open resource
Document URL Open document
Content Type Article
Authors Sharan Randhawa, MSc, Adam Gater, MSc, Roy Bentley, PhD, JD, MSc, on behalf of the expert stakeholder group
Year 2025
Depositor Convergence Chronicles Organisation
Prefix 110.0673
Registered July 17, 2026
Updated July 17, 2026
Status Active
Visibility Public

Cite This Identifier

APA 7th Edition

Click to copy

MLA 9th Edition

Click to copy

Chicago 17th Edition

Click to copy

BibTeX

Click to copy

Persistent Identifier

mdoi:110.0673/CON.2026.00645

Click to copy

About MDOI

MDOI identifiers are permanent and unique identifiers assigned to digital objects to ensure long-term access, tracking, and referencing.

  • MDOI provides a permanent identity for digital objects.
  • Each MDOI is unique and points to one specific resource.
  • The prefix, such as 110.XXXX, identifies the registrant.
  • The suffix identifies the exact digital object.
  • MDOI remains stable even when a website URL changes.
  • It helps prevent broken links in digital publishing.
  • It makes academic and digital resources easier to find and cite.
  • MDOI supports proper tracking and management of digital content.
  • It improves the credibility and visibility of published resources.
  • MDOI ensures digital objects remain accessible, traceable, and reliable over time.
CO
Registered by Convergence Chronicles